Although imatinib mesylate therapy has dramatically improved the prognosis of patients in the advanced phases of chronic myeloid leukemia, room for improvement remains. Tyrosine kinase inhibitors are undergoing evaluation as second-line therapy for patients with imatinib-resistant disease. Kantarjian et al. recently demonstrated that once-daily dasatinib 140 mg is well tolerated and achieves a high response rate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Talpaz, M. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase: results of a phase 2 study. Blood 99, 1928–1937 (2002).
Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemia. N. Engl. J. Med. 354, 2531–2541 (2006).
Kantarjian, H. et al. Phase 3 study of dasatinib 140 mg once daily versus twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15 months median follow-up. Blood 113, 6322–6329 (2009).
Guilhot, F. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143–4150 (2007).
Hochhaus, A. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303–2309 (2006).
Cortes, J. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood 109, 3207–3213 (2006).
Alfonso Quintás-Cardama, A. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. 25, 3908–3914 (2007).
Le Coutre, P. et al. Nilotinib (formerly AMN 107), a highly selective BCR-ABL tyrosine kinase inhibitor, is a active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111, 1834–1839 (2008).
Shah, N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improved tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204–3212 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F. Guilhot is a Consultant, on the Speakers bureau, and receives grant/research support from Bristol-Myers Squibb and Novartis.
Rights and permissions
About this article
Cite this article
Guilhot, F., Roy, L. Dasatinib regimens for patients with chronic myeloid leukemia. Nat Rev Clin Oncol 6, 680–682 (2009). https://doi.org/10.1038/nrclinonc.2009.160
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.160
